Molagri's $5.8M bet: a biopesticide designed to change when the pest does

Molagri, a Toronto biotechnology startup, said it has raised $5.8M in combined pre-seed and seed funding, announced October 14, 2026. Convective Capital led the seed. Julian Capital, the company's earliest backer, led the pre-seed, and the cap table also includes Y Combinator, Superorganism, Robinhood Ventures, Paul Graham and other angels. Molagri did not separately disclose the incremental seed amount or a valuation.

The company develops engineered, non-infectious virus-like particles, or VLPs, as biological delivery vehicles. In its description, a targeting component recognizes receptors in a pest's gut, letting genetic instructions enter cells and cause them to produce an insecticidal payload. Selectivity comes from matching the delivery to the target insect and choosing the payload carefully. Molagri is starting with pests affecting tree nuts and tree fruits.

The founders bring an unusual pedigree to crop protection. CEO Zaky Hassan and CSO Min Jin worked together on human coronaviruses as University of Toronto PhD lab mates before moving their structural-biology and protein-biochemistry training into agriculture. Y Combinator lists Molagri as a Summer 2026 batch company. The team says it mapped a honeybee receptor to understand how its particles could avoid beneficial insects — bringing a pollinator into the design process before a grower ever buys the product.

The financing is slated for scientific recruitment and research at an expanded Toronto laboratory, which now includes biomanufacturing and tissue-culture facilities. Molagri says it has filed a provisional patent covering its targeted delivery system. Its careers page lists four Toronto openings spanning synthetic virology and RNA delivery, insect biology and bioassays, yeast expression and VLP production, and molecular display and binder discovery — a hiring plan that maps the interfaces where a promising particle can fail, from RNA packaging and dose response to purification and storage conditions.

The commercial idea rests on modularity. A change in an insect's receptor could require a different targeting element; resistance to a payload could call for a different way of killing the pest. Molagri aims to make those components replaceable while keeping a common delivery architecture, so growers would get a supplier able to respond when protection weakens rather than a fixed product.

Much remains unproven. In an AgFunderNews interview, Hassan acknowledged that field performance, manufacturing costs, formulation stability and commercial selectivity are still to be established, and said licensing to established crop-protection businesses is among the options under consideration. The company reports an initial grower letter of intent, an expression of interest rather than evidence of paid adoption. Molagri is also exploring how modifications might be assessed without every change losing the speed the modular design is meant to provide; no settled regulatory route for updates exists yet.